These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27364936)

  • 21. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for the management of blood pressure in CKD.
    Ruzicka M; Quinn RR; McFarlane P; Hemmelgarn B; Ramesh Prasad GV; Feber J; Nesrallah G; MacKinnon M; Tangri N; McCormick B; Tobe S; Blydt-Hansen TD; Hiremath S
    Am J Kidney Dis; 2014 Jun; 63(6):869-87. PubMed ID: 24725980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice.
    Carpio EM; Ashworth M; Asgari E; Shaw C; Schartau P; Durbaba S; Nitsch D; Molokhia M
    J Nephrol; 2022 Apr; 35(3):901-910. PubMed ID: 34782969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of SPRINT on the future treatment of hypertension: a mini review.
    Chrysant SG
    Drugs Today (Barc); 2016 Mar; 52(3):193-8. PubMed ID: 27186593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary Biomarkers of Tubular Damage Are Associated with Mortality but Not Cardiovascular Risk among Systolic Blood Pressure Intervention Trial Participants with Chronic Kidney Disease.
    Jotwani VK; Lee AK; Estrella MM; Katz R; Garimella PS; Malhotra R; Rifkin DE; Ambrosius W; Freedman BI; Cheung AK; Raphael KL; Drawz P; Neyra JA; Oparil S; Punzi H; Shlipak MG; Ix JH;
    Am J Nephrol; 2019; 49(5):346-355. PubMed ID: 30939472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.
    Ali S; Dave N; Virani SS; Navaneethan SD
    Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease.
    Chang TI; Wei G; Boucher R; Kramer H; Chertow GM; Cheung AK; Greene T; Whelton PK; Beddhu S
    Kidney360; 2020 May; 1(5):368-375. PubMed ID: 35369376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood pressure control in patients with chronic kidney disease.
    Lee JY; Han SH
    Korean J Intern Med; 2021 Jul; 36(4):780-794. PubMed ID: 34153181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPRINT and the Kidney: What Have We Learned?
    Wells R; Rahman M
    Curr Hypertens Rep; 2018 Sep; 20(11):95. PubMed ID: 30218213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular disease and its relationship with chronic kidney disease.
    Liu M; Li XC; Lu L; Cao Y; Sun RR; Chen S; Zhang PY
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2918-26. PubMed ID: 25339487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled R
    Al Hamarneh YN; Tsuyuki RT; Jones CA; Manns B; Tonelli M; Scott-Douglass N; Jindal K; Tink W; Hemmelgarn BR
    Am J Kidney Dis; 2018 Jan; 71(1):42-51. PubMed ID: 28912054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants.
    Supiano MA; Lovato L; Ambrosius WT; Bates J; Beddhu S; Drawz P; Dwyer JP; Hamburg NM; Kitzman D; Lash J; Lustigova E; Miracle CM; Oparil S; Raj DS; Weiner DE; Taylor A; Vita JA; Yunis R; Chertow GM; Chonchol M
    PLoS One; 2018; 13(9):e0203305. PubMed ID: 30256784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.
    Agarwal A; Wei G; Boucher R; Ahmed F; Beddhu S
    Nephrology (Carlton); 2021 Apr; 26(4):303-311. PubMed ID: 33538091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial.
    Beddhu S; Rocco MV; Toto R; Craven TE; Greene T; Bhatt U; Cheung AK; Cohen D; Freedman BI; Hawfield AT; Killeen AA; Kimmel PL; Lash J; Papademetriou V; Rahman M; Rastogi A; Servilla K; Townsend RR; Wall B; Whelton PK;
    Ann Intern Med; 2017 Sep; 167(6):375-383. PubMed ID: 28869987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.
    Rathi N; Whelton PK; Chertow GM; Cushman WC; Cheung AK; Wei G; Boucher R; Kimmel PL; Bress AP; Kramer HJ; Al-Marji C; Greene T; Beddhu S
    Am J Hypertens; 2019 Nov; 32(12):1170-1177. PubMed ID: 31257407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective.
    Chrysant SG
    Expert Rev Cardiovasc Ther; 2017 Jul; 15(7):517-523. PubMed ID: 28475386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Blood Pressure With the Progression of CKD: Findings From KNOW-CKD Study.
    Lee JY; Park JT; Joo YS; Lee C; Yun HR; Yoo TH; Kang SW; Choi KH; Ahn C; Oh KH; Sung S; Kim SW; Lee J; Han SH;
    Am J Kidney Dis; 2021 Aug; 78(2):236-245. PubMed ID: 33444666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Intensive BP Control in CKD.
    Cheung AK; Rahman M; Reboussin DM; Craven TE; Greene T; Kimmel PL; Cushman WC; Hawfield AT; Johnson KC; Lewis CE; Oparil S; Rocco MV; Sink KM; Whelton PK; Wright JT; Basile J; Beddhu S; Bhatt U; Chang TI; Chertow GM; Chonchol M; Freedman BI; Haley W; Ix JH; Katz LA; Killeen AA; Papademetriou V; Ricardo AC; Servilla K; Wall B; Wolfgram D; Yee J;
    J Am Soc Nephrol; 2017 Sep; 28(9):2812-2823. PubMed ID: 28642330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
    Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
    Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.